Citations

Clear

898 citation(s) found for "Cook, D A".

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure
Steinhardt, Maximilian , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma, Buadi, Francis K. , Dingli, D., Leung, Nelson , Cook, Joselle , Go, Ronald S. , HAYMAN, Suzanne, Kapoor, Prashant , Zanwar, Saurabh , Hellou, Tamer , Fonder, Amie , Hobbs, Miriam, Abdallah, Nadine , Lin, Y., Siddiqui, Mustaqeem, Kyle, R., Kortüm, Martin K., Kumar, Shaji , Dingli, David , Dispenzieri, Angela , Steinhardt, Maximilian , Muchtar, E , Kourelis, Taxiarchis , Buadi, Francis K , Dingli, David , Leung, Nelson , Cook, Joselle M , Go, Ronald S , Gonsalves, Wilson , Kapoor, Prashant , Zanwar, Saurabh S , Binder, Moritz , Hellou, Tamer , Abdallah, Nadine H , Lin, Yi , Siddiqui, Mustaqeem A , Kortüm, Martin , Einsele, Hermann , Rajkumar, S Vincent , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Warsame, Rahma , Hayman, Suzanne R. , Gonsalves, Wilson I. , Binder, Moritz , Siddiqui, Mustaqeem , Kortüm, K. Martin , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

No container title available | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9227260/v1 | PMID 41994108 Get It

Abstract Systemic light chain amyloidosis (AL) arises from monoclonal immunoglobulin light chains, but determinants of progression from precursor states remain poorly defined. In a cross-sectional cohort comprising 1950 systemic AL patients diagnosed 2010-2024, 258 (13.2%) patients with a previously diagnosed plasma cell disorder (PCD) were compared to patients with no prior PCD diagnosis. Patients with monoclonal gammopathy of undetermined signficance (MGUS) and smoldering multiple myeloma (SMM) in the former group had lower difference between involved and uninvolved FLCs (dFLC), higher M-protein, and lower rates of t(11;14) at AL diagnosis. Patients developing AL from SMM had a shorter time to AL (median 34.2 versus 61.3 months) and higher dFLC (median 28.9 versus 11.0 mg/dl) compared to those from MGUS. Patients developing AL after known multiple myeloma (MM) or lymphoplasmacytic lymphoma (LPL) commonly lacked deep hematologic response before AL (≤ very good partial response in 78% of MM, 100% of LPL patients). We additionally studied longitudinally followed cohorts of 3,966 MGUS and 426 (SMM) patients with longitudinal FLC measurements and matched follow-up, in which 1.8% of MGUS and 7.2% of SMM patients developed AL. Those patients who developed AL showed markedly higher dFLC at MGUS/SMM diagnosis and more frequent λ restriction and rates of t(11;14). Higher dFLC was associated with progressively earlier AL development; a 10% cumulative risk occurred at 20 months for patients with a dFLC >80 mg/dL but was not reached if dFLC <10 mg/dL at an estimated median follow-up of 86 months. In multivariable analysis, dFLC >6.4 mg/dL (HR 11.3) and λ isotype (HR 3.6) independently predicted AL, whereas heavy chain secretion was associated with lower risk (HR 0.2 for IgG). These findings indicate that AL risk is primarily driven by cumulative light chain exposure, refining our knowledge of AL pathophysiology and providing guidance for follow-up of patients with elevated dFLC.
Abstract 6261: Inflammation-related exposures and histotype- specific ovarian cancer risk in the Ovarian Cancer Association Consortium (OCAC).
Tworoger, Shelley S., Jensen, Allan, Anton-Culver, Hoda, Bowtell, D., Brooks-Wilson, Angela, Berchuck, A., Cramer, Daniel William, Cunningham, Julie M. , Doherty, Jennifer A., Goode, Ellen L. , Harris, Holly Ruth, Kjaer, Susanne K., Le, Nhu, Lee, A. W., Modugno, Francesmary, Moysich, Kirsten B., Pearce, Celeste, Pike, Malcolm C. , Rossing, Mary A., Schildkrau, Joellen M., Sutphen, Rebecca , Ziogas, A., Wentzensen, Nicolas , Goodman, Marc T , Akonde, Maxwell , Trabert, Britton , Tworoger, Shelley S. , Jensen, Allan , Terry, Kathryn L. , Sampson, Joshua N. , Anton‐Culver, Hoda , Bowtell, David D.L. , Bandera, Elisa V. , Cramer, Daniel W. , Cook, Linda S. , Doherty, Jennifer A. , Goodman, Marc T. , Harris, Holly R. , Kjær, Susanne K. , Modugno, Francesmary , Moysich, Kirsten B., Pearce, Celeste Leigh , Risch, Harvey A. , Rossing, Mary Anne, Stram, Daniel O. , Berg, David Van Den, Webb, Penelope M. , Wu, Anna M.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6261-6261

10.1158/1538-7445.am2026-6261 Get It

Abstract Background: Chronic inflammation is implicated in ovarian carcinogenesis, but how different inflammation-related exposures individually or jointly affect histotype-specific associations remains unclear. Materials and Methods: We pooled data from 16 case-control studies in the Ovarian Cancer Association Consortium to evaluate associations of eight inflammation-related factors (anti-inflammatory: aspirin use, tubal ligation (TL); pro-inflammatory: endometriosis, obesity, lifetime ovulatory cycles (LOC), smoking, pelvic inflammatory disease (PID), polycystic ovary syndrome (PCOS)) with epithelial ovarian cancer (OvC) by histologic subtype. We examined individual associations and clustering of risk factors across histotypes and computed population attributable risk (PAR) for each factor. We assessed additive and multiplicative interactions for exposure combinations. Results: Associations with OvC risk differed by histotype (e.g., high-grade serous: aspirin: OR=0.90; 95%CI 0.82, 0.99; TL: OR=0.80; 95%CI 0.73, 0.88; overall serous: endometriosis: OR=1.17; 95%CI 1.03, 1.31; high LOC: OR=1.42; 95%CI 1.28, 1.58; obesity (low-grade serous): OR=1.50; 95%CI 1.14, 1.98). Clustering analyses showed highly correlated risk profiles in endometrioid and clear cell (r=0.91). High-grade serous and mucinous profiles were moderately correlated with endometrioid and clear cell (r=0.60) tumors. The profile for low-grade serous (r=0.36) tumors was distinct from other histotypes. PAR estimates suggested modifying aspirin use, TL, and LOCs could substantially reduce burdens of endometrioid, clear cell and mucinous tumors. Out of 28 exposure combinations tested in overall OvC and 189 by histotype, we observed 12 interactions. Not using aspirin regularly showed positive additive interactions with obesity and high LOCs, particularly in endometrioid tumors (obesity relative excess risk due to interaction (RERI)=0.74, 95%CI 0.31, 1.18; Pint=0.001 for; LOCs RERI=0.80, 95%CI 0.03, 1.56; Pint=0.04). Not using aspirin regularly also showed a positive additive interaction with endometriosis in clear cell tumors (RERI=1.77, 95%CI 0.03, 3.52; Pint=0.05). Lack of TL showed positive interactions with obesity in endometrioid (RERI=0.86, 95%CI 0.17, 1.53; Pint=0.01) and mucinous (RERI=1.10, 95%CI 0.23, 1.97; Pint=0.01) tumors, while negative additive interactions were observed for smoking and endometriosis in endometrioid tumors (RERI=-1.12, 95%CI -2.19, -0.05; Pint=0.04). A multiplicative interaction was observed between obesity and endometriosis in mucinous tumors (Pint=0.01). Conclusion: The findings suggest ovarian tumorigenesis is strongly shaped by pro- and anti-inflammatory pathways that act largely independently. Further examining these pathways may clarify the origins of histotype heterogeneity and guide prevention strategies. Citation Format: Maxwell Akonde, Britton Trabert, SHELLEY TWOROGER, Allan Jensen, Kathryn L. Terry, Joshua Sampson, Hoda Anton-Culver, David Bowtell, Elisa V. Bandera, Angela Brooks-Wilson, Andrew Berchuck, Daniel William Cramer, Linda S. Cook, Julie M. Cunningham, Jennifer A. Doherty, Ellen L. Goode, Marc T. Goodman, Holly Ruth Harris, Susanne K. Kjaer, Nhu Le, Alice Wen-Ron Lee, Francesmary Modugno, Kirsten B. Moysich, Celeste Pearce, Malcolm C. Pike, Harvey A. Risch, Mary A. Rossing, Joellen M. Schildkrau, Daniel O. Stram, Rebecca Sutphen, David Van Den Berg, Penelope M. Webb, Anna Wu, Argyrios Ziogas, Nicolas A. Wentzensen. Inflammation-related exposures and histotype- specific ovarian cancer risk in the Ovarian Cancer Association Consortium (OCAC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6261.
Neurodegeneration risk variants promote lysosomal TMEM106B fibril accumulation
Replogle, John, Marks, Jordan D. , Fernandez, Martin G , Yu, Dahyun , Winters, Elizabeth, Jawahar, Vidhya Maheswari, Deshmukh, Rishi, Sutanto, Renaldo, Kowal, Isabelle, Frankenfield, Ashley M. , Shi, Rachel , Carlomagno, Yari , Jansen-West, Karen, Kopach, Andrii , Ndayambaje, I. Sandra , Qi, Yue Andy, Shantaraman, Ananth, Pozo-Cabanell, Ignacio, Sheth, Udit , Yue, Mei, Duong, Duc, Bennett, David A, Damme, Markus, Boeve, Brad F, Day, Gregory S, Skarnes, William C, Petersen, Ronald C, Josephs, K., Graff-Radford, Neill, Barmada, Sami J. , Zhang, Yongjie, Hao, Ling , DeTure, Michael , Rawlinson, Bailey, Cook, Erica Engelberg, Casey, Monica Castanedes, Perez, Nathan M, Dickson, Dennis, Liu, Yue, Seyfried, Nicholas T., Wingo, Thomas S, Mosalaganti, Shyamal , Petrucelli, Leonard, Ward, Michael E, Ward, Michael E. , Replogle, John Michael , Todd, Tiffany W. , Engelberg-Cook, Erica , Perez, Nathan, Ward, Michael E , Barmada, Sami , Sheth, Udit , Yuan, Hebao , Kowal, Isabelle , Jansen‐West, Karen , Qi, Yue , Shantaraman, Anantharaman , Duong, Duc, Ferguson, Shawn M. , Bennett, David A. , Daμμe, Markus , Day, Gregory S. , Kellman, Benjamin P. , Skarnes, William C. , Petersen, Ronald C. , Graff‐Radford, Neill R. , McDonough, Justin A. , Prudencio, Mercedes , Dickson, Dennis W. , Wingo, Aliza P. , Liu, Yue, Seyfried, Nicholas T. , Wingo, Thomas S , Petrucelli, Leonard

Mayo Clinic

No container title available | March 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.26.714634 | PMID 41929000 Get It

Variants in TMEM106B and GRN , which encode lysosomal proteins, interact through unknown mechanisms to increase the risk of age-related cognitive decline and neurodegeneration. Here, we show that these variants converge on a single molecular intermediate: the cleaved intra-lysosomal fibril core of TMEM106B, a precursor to amyloid fibrils that accumulate in the aging brain. A protein-coding TMEM106B risk variant (p.T185) drives fibril core accumulation by impairing its degradation and GRN risk variants amplify this effect. Mice over-expressing the fibril core develop hallmarks of neurodegeneration, and cryo-electron tomography reveals intra-lysosomal fibrils in cultured neurons, mice, and diseased human brain. In GRN -mutation carriers, in whom fibril burden is greatest, fibrils extrude through ruptured lysosomal membranes. These findings identify intra-lysosomal TMEM106B fibrillization as a convergent neurodegeneration mechanism and potential therapeutic target.
Large language model scoring of medical student reflection essays: Accuracy and reproducibility of prompt-model variations
Cook, David A. , Laack, Torrey A. , Pankratz, V. Shane

Mayo Clinic

No container title available | March 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.20.26348918 Get It

Abstract Introduction Evaluate large language models (LLMs) for scoring medical student essays, and compare various prompting techniques and models. Methods OpenAI GPT scored 51 medical student reflection essays (15 real, 36 fabricated) using a previously-reported 6-point rubric (April-May 2025). We compared 29 prompt-model conditions by systematically varying the LLM prompts (including the persona, scoring rubric, few-shot learning [exemplars], chain-of-thought reasoning, and temperature), fine-tuning, and model (including GPT-4.1, GPT-4.1-mini, GPT-o4-mini, and GPT-4-Turbo). Outcomes were accuracy (compared with human raters, measured using single-score intraclass correlation coefficient [ICC] and mean absolute difference [MAD; zero indicates perfect agreement]), within-condition reproducibility, and cost. Results Across all conditions, it took mean (SD) 3.73 (3.12) seconds to score 1 essay. The cost to score 100 essays was USD $0.04 for GPT-4.1-mini, $0.21 for GPT-4.1, $0.57 for GPT-4.1 with 3 exemplars, and $2.00 for fine-tuned GPT-4.1. When the one-time cost of fine-tuning was amortized across 10,000 essays, the cost for fine-tuned GPT-4.1 was $0.20 per 100. Accuracy was “almost perfect” (ICC >0.80) for 28/29 conditions (97%). Fine-tuned models were more accurate than non-fine-tuned models (MAD difference –0.24 [95% CI, –0.34, –0.14]). Conditions with exemplars were more accurate than those without (MAD difference –0.44 [CI, –0.57, –0.31]). Accuracy progressively decreased as 6, 3, 1, and 0 rubric levels were explicitly defined in the prompt (P<.001). Contrary to hypotheses, accuracies for chain-of-thought prompts and variations in temperature and persona were not significantly different from the baseline prompt. Reproducibility ICC was >0.80 for 28/29 conditions (97%). Discussion Automated LLM essay scoring demonstrated near-perfect accuracy and reproducibility for most prompt-model conditions. Fine-tuned models and prompts with exemplars had higher accuracy but higher cost. Fine-tuned models had lower per-essay costs for larger essay volumes. For smaller volumes, non-fine-tuned GPT-4.1 provided excellent results at moderate cost. GPT-4.1-mini provided very good results at low cost.
Virtual Multidisciplinary Gastrointestinal Care Clinic Improves Patient Engagement, Satisfaction, and Outcomes at Reduced Costs and Healthcare Utilization: A Prospective Cohort Study
Berry, Sameer, Varma, Sanskriti , Basnayake, Chamara , Ahn, Joseph , Berinstein, J, Chan, Walter W. , Allen, John, Chey, William, Berry, Sameer , Berry, Sameer K , Ahn, Joseph C , Berinstein, Jeffrey , Chan, Walter , Cook, David J. , Allen, John I.

Mayo Clinic

American Journal of Gastroenterology | March 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004002 | PMID 41860134 Get It

INTRODUCTION: Chronic gastrointestinal (GI) conditions, including irritable bowel syndrome and other disorders of gut-brain interaction, are prevalent and costly, and fragmented care contributes to suboptimal outcomes. Virtual and multidisciplinary care models may improve outcomes. Objectives: We aimed to (i) characterize patients receiving virtual GI care, (ii) report patient engagement with and patient-reported outcomes after virtual multidisciplinary care, and (iii) report healthcare utilization and costs from a payer perspective among patients vs propensity score-matched controls identified from claims data. METHODS: We collected descriptive data on patient demographics, clinic provider visits, symptoms, and patient-reported outcomes from 3/2021 to 9/2022. To evaluate healthcare utilization and costs, we conducted difference-in-difference analyses using claims data compared with a propensity score-matched control group. RESULTS: Among 234 patients (71% women, mean age 45.4 ± 13.2 years), 51% received a new GI diagnosis, predominately disorders of gut-brain interaction (63%). Engagement criteria were met by 80% (n = 187), who completed a mean of 10 visits and median time-to-first appointment of 6 days. Dietitians (93%), psychologists (76%), and health coaches (64%) were frequently used. Engaged patients exhibited significant improvements from preclinic to postclinic in irritable bowel syndrome severity (226.7–145.6), symptom control (20.2%–86.6%), quality-of-life dysphoria (27.5–32.8), missed workdays (1.0–0.7), and satisfaction (37.4%–96.3%) (all P < 0.05). Compared with matched controls, a significantly smaller percent of patients had imaging (15% vs 44%; P < 0.0001) and GI-related emergency department visits (4% vs 10%; P = 0.0028), which contributed to reductions in GI-related costs ($443 per member per month; P = 0.047) and all-cause costs ($676 per member per month; P = 0.043), equating to annualized savings of $5,316 and $8,112, respectively. DISCUSSION: Virtual multidisciplinary GI care was associated with high engagement, improved clinical outcomes, and reduced healthcare utilization and costs.
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma
Abdallah, Nadine, White, Thomas, Heeren, Amanda A., Wildes, Tanya, Marar, Rosalyn, Yee, Claire , Bodily, Anna, Kotajarvi, Brian R., Aug, Sarah, Kapoor, Prashant , Dispenzieri, Angela, Hayman, Suzanne, Dingli, David, Gonsalves, Wilson, Cook, Joselle, Zanwar, Saurabh , Lin, Y., Kourelis, Taxiarchis, Gertz, MA, Warsame, Rahma, Rajkumar, S, LeBrasseur, Nathan, Kumar, Shaji, Weivoda, Megan , Abdallah, Nadine H , Heeren, Amanda, Marar, Rosalyn , Yee, Claire , Kotajarvi, Brian, Buadi, Francis K , Kapoor, Prashant , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Lin, Yi , Kourelis, Taxiarchis , Gertz, Morie A , Rajkumar, S Vincent , Sfeir, Jad G , Kumar, Shaji K , Weivoda, Megan , Abdallah, Nadine , Smith, Byron H. , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Hayman, Suzanne, Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Kourelis, Taxiarchis , Warsame, Rahma , Sfeir, Jad , LeBrasseur, Nathan K

Mayo Clinic

No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8605152/v1 | PMID 41890848 Get It

Abstract Frailty predicts adverse outcomes in multiple myeloma (MM), yet an objective frailty biomarker is lacking. Circulating senescence-associated secretory phenotype (SASP) factors correlate with frailty and adverse outcomes in chronic diseases, but their relevance in MM is unclear. In this study, we investigated the relationship between 36 plasma SASP factors, frailty, and clinical outcomes in: (1) a historical cohort using stored specimens from 59 patients with newly diagnosed MM, and (2) a prospective cohort of 36 patients initiating new MM treatment. Several SASP factors were significantly associated with frailty after adjusting for age, sex, and body mass index; GDF-15, TNF-RI, IL-6, and IL-8 showed positive correlations with both cumulative-deficit based and physical frailty indices. Additionally, significant age-adjusted associations were observed between SASP factors and treatment outcomes, including overall survival (OS), high-grade toxicity, and healthcare utilization. We developed a 5-factor SASP model that demonstrated superior predictive performance for OS compared to chronological age, R-ISS stage, and clinical frailty, and TNF-RI alone (5-year OS AUC: 0.90). These findings highlight the association between senescence biomarkers and frailty and OS, and support further investigation of SASP factors as objective frailty biomarkers in MM.
Germline genetic variants and epilepsy surgery response: individual-participant pooled analysis of 269 patients
Ivaniuk, Alina, Bajaj, Sunanjay , Bosselmann, Christian M, Koh, Hyun Yong, Pestana-Knight, E, Zhang, Xiaoming, Bingaman, William, Najm, Imad, Shah, Manish N., Tandon, N., Allmen, Gretchen Von , Lhatoo, Samden D. , Tatum, William, Freund, Brin , Miller, Kai J. , Wirrell, Elaine, Coryell, J., Schreiber, John, Perry, Scott, Lal, Dennis , Ivaniuk, Alina , Ivaniuk, Alina , Boßelmann, Christian M. , Koh, Hyun Yong , Pestana‐Knight, Elia , Bingaman, William , Najm, Imad , Shah, Manish N. , Tatum, William, Wirrell, Elaine , Fine, Anthony L. , Coryell, Jason , Schreiber, John R. , Perry, Scott

Mayo Clinic

No container title available | March 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.10.26347961 Get It

Abstract Background Genetic testing is increasingly used in presurgical evaluation, but the yield of resection across germline genetic epilepsies remains uncertain. Methods We conducted a systematic review of MEDLINE (PubMed) and Scopus and added cases from three institutional cohorts and the Pediatric Epilepsy Research Consortium (PERC) databases, including individuals with pathogenic/likely pathogenic germline variants besides tuberous sclerosis and neurofibromatosis who underwent resection or laser ablation. Etiologies were grouped into biologically informed categories (GATORopathies, vascular, overgrowth, CNVs, channelopathies, synaptopathies, other). Primary outcome was seizure freedom (Engel I) at last follow-up. Group comparisons used Fisher’s exact and Kruskal–Wallis tests (α=0.05; Bonferroni when applicable). Prespecified sensitivity analyses stratified by lesional status, excluded GATORopathies, and restricted to literature-only cases. Results We included 223 literature cases (64 studies), 35 institutional cases, and 11 PERC cases (n=269). Median follow-up was 24 months (IQR 12–48.0). Seizure freedom was achieved in: vascular disorders 14/19 (73.6%), GATORopathies 79/120 (67.5%), CNVs 18/31 (66.7%), overgrowth 7/13 (53.8%), other 16/25 (41.7%), channelopathies 13/43 (33.3%), and synaptopathies 4/18 (22.2%) (overall p<0.001). Among cases with known imaging, 208/253 (82.2%) had epileptogenic MRI lesions, including 64% of channelopathies and 80% of the synaptopathies. In univariate contrasts (each category vs all others), odds of seizure freedom were higher for vascular disorders (2.66-fold, 95% CI 0.87–9.72) and GATORopathies (2.46-fold, 95% CI 1.46–4.18), and lower for synaptopathies (∼4.2-fold lower, OR 0.24, 95% CI 0.05– 0.78) and channelopathies (∼4.5-fold lower, OR 0.22, 95% CI 0.09–0.48). Direction and magnitude were consistent across prespecified sensitivity analyses (lesional-only, literature-only, exclusion of GATORopathies). Conclusions Resective surgeries can be effective in germline genetic epilepsies, but outcomes vary by pathway. Disorders with discrete, lesional substrates (GATORopathies, vascular) show the highest likelihood of seizure freedom, whereas channelopathies and synaptopathies, despite the presence of MRI lesions, have substantially lower yields even in lesional cases. Prospective, genotype-aware surgical registries with standardized reporting (EEG, imaging, pathology) and time-to-event outcomes are needed to refine the selection of surgical candidates and quantify seizure and non-seizure-related outcomes.
Diabetic striatopathy associated with nonketotic hyperglycemia
Arguinchona, Joseph , Ross, Jeffrey S, Ranasinghe, Tamra , Cook, Curtiss B.

Mayo Clinic

JCEM Case Reports | March 2, 2026 | Volume: 4 | Issue: 6 | Pages: No page available

10.1210/jcemcr/luag075 | PMID 42064722 Get It